Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency


Bone marrow transplantation (BMT) for severe combined immunodeficiency (SCID) with human leukocyte antigen (HLA)-identical sibling donors but no pretransplantation cytoreduction results in T-lymphocyte engraftment and correction of immune dysfunction but not in full hematopoietic engraftment. A case of a 17-month-old girl with adenosine deaminase (ADA) deficiency SCID in whom full hematopoietic engraftment developed after BMT from her HLA-identical sister is reported. No myeloablative or immunosuppressive therapy or graft-versus-host disease (GVHD) prophylaxis was given. Mild acute and chronic GVHD developed, her B- and T-cell functions became reconstituted, and she is well almost 11 years after BMT. After BMT, repeated studies demonstrated: (1) Loss of a recipient-specific chromosomal marker in peripheral blood leukocytes (PBLs) and bone marrow, (2) conversion of recipient red blood cell antigens to donor type, (3) conversion of recipient T-cell, B-cell, and granulocyte lineages to donor origin by DNA analysis, and (4) increased ADA activity and metabolic correction in red blood cells and PBLs. (Blood. 2001;97:809-811)

© 2001 by The American Society of Hematology

Severe combined immunodeficiency (SCID) involves a failure of T cells to proliferate to various stimuli and a failure of B cells to produce specific antibodies.1,2 Adenosine deaminase (ADA) deficiency, an autosomal recessive genetic defect, produces a SCID phenotype.3,4 The enzyme defect leads to an abnormality in purine nucleoside metabolism that interferes with lymphocyte viability and function. ADA-deficient SCID is characterized by growth delay, candidiasis, respiratory infections, opportunistic infections, and, without specific therapy, early death.5 Low or absent ADA activity in erythrocytes or other cells is diagnostic.

Bone marrow transplantation (BMT) is effective therapy for SCID. The profound T-cell dysfunction associated with ADA-deficient SCID prevents graft rejection and permits BMT without conditioning with an HLA-matched sibling donor.1,2,6 Success rates are greater than 90%, with full recovery of T-cell and B-cell functions.6 Complete T-cell engraftment is routinely demonstrated, and approximately 50% of patients demonstrate engraftment of donor B cells.7 Without conditioning, host hematopoiesis persists with no evidence of myeloid or erythroid engraftment.5,7,9

Laboratory evaluation revealed normal hemoglobin and platelet counts. The white blood cell count was 1600/cmm (normal, 6000-17 000/cmm) and consisted of 10% neutrophils, 20% lymphocytes, 65% monocytes, and 4% eosinophils. Liver function test results were normal. Titers were negative for human immunodeficiency virus, cytomegalovirus, hepatitis B virus, herpes simplex virus, Epstein-Barr virus, adenosivirus, poliovirus, Toxoplasma, and Chlamydia trachomatis.

ADA activity was deficient in erythrocytes and in peripheral blood mononuclear cells; purine nucleoside phosphorylase (PNP) activity was normal in both cell types (Table 1). Metabolic findings in erythrocytes were consistent with ADA deficiency, including elevated deoxyadenosine nucleotide (dAXP) of 0.491 mol/mL packed cells (normal, less than 0.002 µM/mL), and reduced S-adenosylhomocysteine hydrolase activity of 0.42 nmol/h/mg protein (normal, 4.2 1.9).3

A 3-year-old sister was HLA-identical (A2, A3, B35, B27, Cw2, Cw4, DRB1*01, and DRB1*04). Without myeloablative or immunosuppressive therapy, the patient was infused with 7.6 106 unfractionated nucleated marrow cells per kilogram from her sister. After BMT, the patient engrafted rapidly, remained well, and required no blood products (Figure 1). Biopsy-proven grade I skin graft-versus-host disease (GVHD) developed at day 39 after BMT and resolved with topical corticosteroids. Three months after BMT, she developed vomiting and diarrhea with elevated absolute neutrophil and lymphocyte counts (Figure 1). Liver function tests revealed the following values: aspartate aminotransferase, 270 IU/L (normal, 0-30 IU/L); alanine aminotransferase, 262 IU/L (normal, 7-56 IU/L); and γ-glutamyl transpeptidase, 123 IU/L (normal, 8-78 IU/L). The illness resolved rapidly, and liver function findings were normal 3 months later.

Eleven months after BMT, lichenoid skin lesions developed that were consistent with chronic GVHD; they completely resolved after 11 months of oral and topical corticosteroid therapy. A dermatofibrosarcoma protuberans was completely excised from the patient’s left forearm 8 years after
Table 1. Adenosine deaminase and purine nucleoside phosphorylase activity in red blood cells and peripheral blood mononuclear cells

<table>
<thead>
<tr>
<th></th>
<th>Erythrocytes</th>
<th>Mononuclear cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ADA</td>
<td>PNP</td>
</tr>
<tr>
<td>Patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before BMT</td>
<td>0.98</td>
<td>1259</td>
</tr>
<tr>
<td>After BMT</td>
<td>17.6 ± 6.6</td>
<td>1585 ± 104</td>
</tr>
<tr>
<td>Donor</td>
<td>18.4</td>
<td>1744</td>
</tr>
<tr>
<td>Normal levels</td>
<td>63 ± 41</td>
<td>1336 ± 441</td>
</tr>
</tbody>
</table>

ADA indicates adenosine deaminase; PNP, purine nucleoside phosphorylase; BMT, bone marrow transplantation.

Enzyme activities are expressed as nmol/h/mg protein. Pre-BMT patient and donor values are from single samples. Normal values and post-BMT data for the patient are given as mean ± SD. Post-BMT patient samples were obtained on 4 occasions—at 16 months, 26 months, 47 months, and 127 months after transplantation.

Results and discussion

Allogeneic BMT is effective treatment for various inherited defects of the pluripotent hematopoietic progenitor cell (HPC). An immunosuppressive and myeloablative preparative regimen is usually necessary to suppress the host’s immune system to prevent rejection of the infused stem cells. The only exception to the above experience is in BMT for SCID, when a matched sibling or a T-depleted haploidentical stem cell donor is available. Because of the host’s severe immune dysfunction, the donor graft is not rejected. Only T-cell progenitors, which have a selective growth advantage over endogenous host T cells, engraft. After BMT all erythroid and myeloid precursors remain of recipient origin. After unconditioned BMT for SCID with an HLA-matched sibling donor, T-cell function is restored in a few weeks and B-cell function in a few months. Normalization of B-cell function does not necessarily reflect donor B-cell engraftment. In many cases, B-cells remain partially or completely of host origin, but they function normally in the presence of donor T cells. Natural killer cells may also be of donor, host, or mixed origin after unconditioned BMT.

We report a patient with classic ADA-deficient SCID, heterozygous for 2 previously reported ADA missense mutations, R101Q (exon 4) and R156C (exon 5). Before BMT she had lymphopenia, absent B-cells, an inverted CD4/CD8 ratio, absent natural killer activity, and markedly depressed in vitro mitogen response to pokeweed, concanavalin A, and phytohemagglutinin. Her bone marrow had normal cellularity with depressed T- and B-cell numbers for her age. After BMT, all the above evaluations gradually normalized. In addition, we found multiple markers confirming complete erythroid and myeloid engraftment.

Recipient and donor were both blood group A Rh-positive. The recipient (Jkα negative, E positive) had complete conversion to donor erythrocyte antigens (Jkα positive, E negative) when studied at 4 and 26 months after BMT. Anti-B was weakly detected before BMT and strongly detected 26 months after BMT.

Before BMT, all mitoses in the BM demonstrated the 1qh polymorphism. At 1 and 3 months after BMT, analysis of PHA-stimulated PBLs demonstrated mixed chimerism. Full donor engraftment was found at 6 months, and all subsequent findings of PBLs and BM (at 1 and 8 years) have remained 100% donor origin.

After BMT, ADA activity in erythrocytes and blood mononuclear cells increased to the level found in the donor (Table 1). Erythrocyte dAXP level was less than 0.01 nmol/mL packed cells in all samples obtained after BMT. All the above studies demonstrated complete T, B, erythroid, and myeloid cell engraftment from 6 months after BMT without any evidence of mixed chimerism.

After BMT the host HPC ceased to function in our patient. Because no episode of pancytopenia or marrow aplasia occurred, transient mixed chimerism of host and donor hematopoiesis must
have developed. Over time the host stem cells ceased to function, and only the donor stem cells and their progeny persisted. The most appealing speculation for this observation is the development of donor T-cell–mediated GVHD reaction that targeted and destroyed the host HPC without other manifestations of significant GVHD. Approximately 3 months after transplantation, the child had an episode of vomiting, diarrhea, and elevated liver enzyme levels. At that time a significant increase in hemoglobin, platelet, absolute neutrophil, and absolute lymphocyte counts were found that persisted into long-term follow-up (Figure 1). The patient’s cytogenetic studies also changed during this period, from 50% to 80% donor cells, with 100% donor cells present at 6 months and later (Figure 1).

It has been reported that severe GVHD with pancytopenia and aplasia develop in infants with SCID after in utero engraftment with maternal cells.23 In addition, transfusional GVHD in immunodeficient infants is characterized by the development of severe GVHD and aplastic anemia, as is transfusional GVHD in immunocompetent patients after open heart surgery.22,23 In all the above examples, donor T-lymphocytes mediate host hematopoietic stem cell destruction and lead to the development of marrow aplasia and severe pancytopenia. However, unlike our experience, fatal GVHD developed in all the reported recipients.

An alternative hypothesis is that because ADA-sufficient cells (donor) have a selective growth advantage over ADA-deficient cells (host), donor HPC engraftment would occur. However, in all reported cases of BMT in ADA SCID, host erythropoiesis and myelopoiesis persist.

Our observation is certainly rare. The Buckely et al21 survey of 87 patients with SCID who underwent either HLA-haploididentical or HLA-identical BMT without a preparative regimen or GVHD prophylaxis found no case of complete hematopoietic engraftment, though red cell typing was not specifically noted. Haddad et al8 recently reported that 2 of 8 patients with SCID with B cells had evidence of some donor-derived monocytes after HLA-haploididentical, T-cell–depleted BMT without a preparative regimen. None of the 5 HLA-identical BMT patients had donor-derived monocytes. We suggest that investigators following up patients with SCID who underwent transplantation without a preparative regimen look for evidence of partial or complete myeloid and erythroid engraftment in their patients. Identification and further study of this phenomenon may lead to a better understanding of allogeneic tolerance.

Acknowledgments

We thank Dr F. X. Arredondo-Vega for assistance in performing ADA genotype analysis and Dr Roger Kobayashi for referring the patient to us.

References

16. Hershfield MS, Buckley RH, Greenberg ML, et al. Identification and further study of this phenomenon may lead to a better understanding of allogeneic tolerance.
Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency


Updated information and services can be found at:
http://www.bloodjournal.org/content/97/3/809.full.html

Articles on similar topics can be found in the following Blood collections
  Brief Reports (1931 articles)
  Clinical Trials and Observations (4514 articles)
  Transplantation (2215 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml